The Schepens Eye Research Institute, Inc.

Vegenics Pty Limited

Ma, Jie

Lashkari, Kameran

Opthea Limited

Jie Ma

Kameran Lashkari

Megan E Baldwin

The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.

Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization

The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularization. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.

Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis

Growing community of inventors

Boston, MA, United States of America

Jie Ma